Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen acquires 'cheaper, oral' alternative to Repatha

This article was originally published in Scrip

Executive Summary

Amgen is to acquire Dezima Pharma B.V., which recently published highly positive Phase IIb data with its CETP inhibitor TA-8995 suggesting it might have potential as a more cost-effective option for lowering cholesterol than the PCSK9 inhibitor approach. Amgen just had its cholesterol-lowering injectable PCSK9 inhibitor antibody Repatha (evolocumab) approved.

You may also be interested in...



BioGeneration Ventures Leads Europe's Seed Investing With New Fund

A new VC fund raised by the Netherlands firm, BioGeneration Ventures, has attracted pharma corporate and private investors and is now one of the largest-ever funds focused on making seed investments in European biotech companies.

Amgen Focuses On Pipeline As Mature Products Face Declining Demand

Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.

Bio Boost For Benelux As BioGeneration Ventures Beats Fund Target

Dutch life sciences venture capital firm BioGeneration Ventures has exceeded the €50m target in a third closing of its BGV III fund, raising €66m. It intends to focus its investments on firms in the Netherlands, Belgium, Luxembourg and Germany, and expects to secure further funds, reaching the maximum fund size of €75m by the end of 2017.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC029775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel